- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00151476
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
A Registry-Based Observational Study Assessing Clinical Outcomes In Familial Adenomatous Polyposis In Patients Receiving Celecoxib (Celebrex(Registered), Onsenal(Registered)) Compared With Control Patients
This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib.
Both retrospective and prospective data will be utilized. No sampling methods apply.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X5
- Pfizer Investigational Site
-
-
-
-
Copenhagen
-
Hvidovre, Copenhagen, Denmark, DK-2650
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spain, 08036
- Pfizer Investigational Site
-
-
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Celecoxib Treated Patients:
- Diagnosis of FAP based on the expression of the FAP phenotype.
- Celecoxib treatment prescribed outside of a clinical trial setting with expected duration of celecoxib treatment of at least six months.
Historical/Concurrent Control Patients:
- Diagnosis of FAP based on the expression of the FAP phenotype.
- Be greater than or equal to 12 years old at the time of study enrollment.
- Have an endoscopically assessable colonic, rectal, ileal pouch and/or gastroduodenal segment.
- For the group of post-surgical patients, IRA or IPAA performed from 1985 onward (in order to assure standardized surgical techniques and post-surgical management). Patients whose primary colorectal surgery was performed prior to 1985 will not be eligible to serve as historical controls.
Exclusion Criteria:
Celecoxib Treated Patients:
- Have received a pharmacological treatment (other than celecoxib) within the last 3 months for their FAP disease including treatment of any extracolonic manifestation of FAP.
- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months, other than celecoxib, for any reason.
Historical/Concurrent Control Patients:
- Have pharmacological treatment recorded for their FAP disease at the defined index date.
- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months for any reason.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Celecoxib - Routine Medical Care
800 mg total daily dosing
|
800 mg total daily dosing
Other Names:
|
Control Group - Routine Medical Care
Observation of subjects treated with routine medical care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time From Ileorectal Anastomosis (IRA) to Time of First Excisional Polypectomy of a Rectal Polyp Post IRA
Time Frame: Up to 8 years prior to baseline
|
Time(months): [date of first excisional polypectomy of rectal polyp post IRA minus date of prior IRA plus 1] divided by 30.44.
Baseline = start of study follow-up: start of on-study celecoxib treatment period for celecoxib-treated subjects and comparable to index date for control subjects.
Index date calculated as Matched Celecoxib-treated patients: number of days from most recent FAP-related surgery (IRA or IPAA) to start of study follow-up; add this number of days to matched control patient's most recent FAP-related surgery date=index date for Matched Control.
|
Up to 8 years prior to baseline
|
Time From Start of Study Follow-up to the Time of First Excisional Polypectomy of a Rectal Polyp Post IRA
Time Frame: Baseline, Up to 60 months post-baseline
|
Time(months): [date of first excisional polypectomy of rectal polyp post IRA minus date of start of study follow-up plus 1] divided by 30.44.
|
Baseline, Up to 60 months post-baseline
|
Time From Ileopouch Anal Anastomosis (IPAA) to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA
Time Frame: Up to 15 years prior to baseline
|
Time (months): [date of first excisional polypectomy of a rectal polyp post IPAA minus date of prior IPAA plus 1] divided by 30.44.
Baseline = start of study follow-up: start of on-study celecoxib treatment period for celecoxib-treated subjects and comparable to index date for control subjects.
Index date calculated as Matched Celecoxib-treated patients: number of days from most recent FAP-related surgery (IRA or IPAA) to start of study follow-up; add this number of days to matched control patient's most recent FAP-related surgery date=index date for Matched Control.
|
Up to 15 years prior to baseline
|
Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA
Time Frame: Baseline, Up to 60 months post-baseline
|
Time (months): [date of first excisional polypectomy of rectal polyp post IPAA minus date of start of study follow-up plus 1] divided by 30.44.
|
Baseline, Up to 60 months post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time From Most Recent Prior FAP-related Surgical Event or Onset of FAP Phenotype to Time of First Excisional or Ablational Event for Rectal, Colonic, Pouch, or Duodenal Adenomas (Duodenal Adenomatous Polyps)
Time Frame: Up to 15 years prior to baseline
|
Time (months): [date of first excisional or ablational event for colonic, pouch, or duodenal adenomas occuring after date of most recent prior FAP-related surgical event or date of FAP diagnosis minus date of most recent prior FAP-related surgical event or date of FAP diagnosis plus 1] divided by 30.44.
|
Up to 15 years prior to baseline
|
Time From Start of Study Follow-up to Time of First Excisional or Ablational Event for Rectal, Colonic, Pouch, or Duodenal Adenomas
Time Frame: Baseline, Up to 60 months post-baseline
|
Time (months): [date of first excisional or ablational event for colonic, pouch, or duodenal adenomas, occurring after date of most recent prior FAP-related surgical event, or date of FAP diagnosis minus date of start of study follow-up plus 1] divided by 30.44.
|
Baseline, Up to 60 months post-baseline
|
Time From Most Recent Prior FAP-related Surgical Event or Onset of FAP Phenotype to Time of First FAP-related Adverse Event
Time Frame: Up to 15 years prior to baseline
|
Time (months): [date of first FAP-related adverse event, occurring after the date of most recent prior FAP-related surgery, or date of FAP diagnosis minus date of most recent prior FAP-related surgery, or date of FAP diagnosis plus 1] divided by 30.44.
FAP-related adverse event defined as any FAP related cancers, desmoid tumors requiring procedural intervention, hospitalizations or procedural interventions, or death related to FAP (i.e., as a consequence of FAP, FAP complications, or a procedure or drug used to treat FAP-related medical problems).
|
Up to 15 years prior to baseline
|
Time From Start of Study Follow-up to Time of First FAP-related Adverse Event
Time Frame: Baseline, Up to 60 months post-baseline
|
Time (months): [date of first FAP-related adverse event, occurring after the date of the most recent prior FAP-related surgery, or date of FAP diagnosis minus date of start of study follow-up plus 1] divided by 30.44.
FAP-related adverse event defined as any FAP related cancers, desmoid tumors requiring procedural intervention, hospitalizations or procedural interventions, or death related to FAP (i.e., as a consequence of FAP, FAP complications, or a procedure or drug used to treat FAP-related medical problems).
|
Baseline, Up to 60 months post-baseline
|
Time From Post IRA to Time of Conversion From IRA to IPAA
Time Frame: Up to 15 years prior to baseline
|
Time (months): [date of IPAA minus date of prior IRA plus 1] divided by 30.44.
|
Up to 15 years prior to baseline
|
Time From Start of Study Follow-up to Time of Conversion From IRA to IPAA
Time Frame: Baseline, Up to 60 months post-baseline
|
Time (months): [date of IPAA minus date of start of study follow-up plus 1] divided by 30.44.
|
Baseline, Up to 60 months post-baseline
|
Duodenal Adenoma Burden as Measured by Spigelman Stage
Time Frame: Baseline, 6 to 14 months post-baseline, End of study (EOS)
|
Number of subjects with polyp burden as assessed in most recent prior polyps evaluation: Spigelman stage provides index of disease severity based on number of polyps, polyp size, histology, and dysplasia; range is Stage 0 (none) to Stage IV (severe).
EOS: endoscopic examination closest to end of on-study celecoxib or index period (within 6 months of end of celecoxib or index period and prior to intake of any exclusionary medications after baseline).
Spigelman Stage not completed as staging data largely missing; see measure: Duodenal adenoma burden as measured by polyp counts.
|
Baseline, 6 to 14 months post-baseline, End of study (EOS)
|
Rectal or Pouch Adenoma Burden Based on Polyp Counts
Time Frame: Baseline, 6 to 14 months post-baseline, EOS
|
Number of subjects with polyp burden as assessed in most recent prior polyps evaluation: attenuated: <100 polyps, mild: between 100 to 1000 polyps, severe: >1000 polyps.
EOS: endoscopic examination closest to end of on-study celecoxib or index period (within 6 months of end of celecoxib or index period and prior to intake of any exclusionary medications after baseline).
|
Baseline, 6 to 14 months post-baseline, EOS
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Syndromes, Hereditary
- Adenomatous Polyps
- Adenoma
- Intestinal Polyposis
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Adenomatous Polyposis Coli
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- NQ4-00-02-012
- A3191167
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Adenomatous Polyposis (FAP)
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedFamilial Adenomatous Polyposis (FAP)Italy
-
S.L.A. Pharma AGCompletedFAP | Familial Adenomatous Polyposis ColiUnited Kingdom
-
michal rollUnknownFAP-Familial Adenomatous PolyposisIsrael
-
michal rollUnknownFAP-Familial Adenomatous Polyposis
-
Tel-Aviv Sourasky Medical CenterUnknownFamilial Adenomatous Polyposis | FAP | FAP Gene Mutation
-
M.D. Anderson Cancer CenterCompletedAttenuated Familial Adenomatous Polyposis | Deleterious Familial Adenomatous PolyposisUnited States
-
National Cancer Institute (NCI)CompletedFamilial Adenomatous Polyposis | Attenuated Familial Adenomatous PolyposisUnited States, Puerto Rico
-
National Cancer Institute (NCI)RecruitingFamilial Adenomatous Polyposis | Colorectal Carcinoma | Attenuated Familial Adenomatous Polyposis | Duodenal CarcinomaUnited States, Puerto Rico
-
Copenhagen University Hospital, HvidovreCompletedDuodenal Cancer | Duodenal Polyposis | Familial Adenomatous PolyposesDenmark
-
Dr. Ersin Arslan Education and Training HospitalCompleted
Clinical Trials on Celecoxib
-
Chong Kun Dang PharmaceuticalCompletedOsteoarthritis HandKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersSingapore
-
Yooyoung Pharmaceutical Co., Ltd.CliPS Co., LtdCompletedOsteoarthritis, KneeKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.CliPSBnCRecruitingOsteoarthritis, KneeKorea, Republic of
-
Samsung Medical CenterThe Korean Urological AssociationWithdrawnBenign Prostatic HyperplasiaKorea, Republic of
-
Seoul National University HospitalCompletedIntracerebral HemorrhageKorea, Republic of
-
Dr. Reddy's Laboratories LimitedCompleted
-
Amsterdam UMC, location VUmcNetherlands Brain FoundationRecruitingInflammation | Depressive Disorder, MajorNetherlands
-
Targeted Therapy Technologies, LLCRecruitingMacula Edema | Epiretinal Membrane | Branch Retinal Vein Occlusion | Radiation Retinopathy | Central Serous Retinopathy With Pit of Optic Disc | Commotio Retinae | VitritisUnited States
-
Peking University Third HospitalNot yet recruiting